Dissociation of growth hormone and prolactin response to levodopa during pyridoxine administration.
500 mg of levodopa was administered orally to 8 normal subjects and induced an increase of growth hormone (GH) and a decrease of prolactin (PRL) secretion. The levodopa-induced GH release was inhibited by an intravenous infusion of pyridoxine; on the contrary, the PRL response to levodopa was enhanced by pyridoxine infusion. This dissociation of GH and PRL responses to levodopa during pyridoxine infusion appears to be mediated by peripheral acceleration of the conversion of levodopa to dopamine. Since dopamine does not penetrate the blood-brain barrier, the enhanced PRL decrease observed during pyridoxine infusion might be explained only on the basis of a mechanism of action exerted by dopamine on extra blood-brain barrier sites.
D000328:Adult; D001812:Blood-Brain Barrier; D004298:Dopamine / Q000378:metabolism; D004357:Drug Synergism; D005260:Female; D013006:Growth Hormone / Q000378:metabolism*; D006801:Humans; D007980:Levodopa / Q000378:metabolism / Q000494:pharmacology*; D008297:Male; D011388:Prolactin / Q000378:metabolism*; D011389:Prolactin Release-Inhibiting Factors / Q000378:metabolism; D011736:Pyridoxine
D007980:Levodopa; D011388:Prolactin; D013006:Growth Hormone; D011389:Prolactin Release-Inhibiting Factors; D011736:Pyridoxine; D004298:Dopamine